Your browser doesn't support javascript.
loading
Exendin-4 enhances the sensitivity of prostate cancer to enzalutamide by targeting Akt activation.
Wenjing, He; Shao, Yuanyuan; Yu, Yi; Huang, Wei; Feng, Guoliang; Li, Junhe.
Afiliação
  • Wenjing H; Institute of Urology, the First Affiliated Hospital of Nanchang University, Nanchang, China.
  • Shao Y; Department of Oncology, the First Affiliated Hospital of Nanchang University, Nanchang, China.
  • Yu Y; Department of Oncology, the First Affiliated Hospital of Nanchang University, Nanchang, China.
  • Huang W; Department of Oncology, the First Affiliated Hospital of Nanchang University, Nanchang, China.
  • Feng G; Department of Oncology, the First Affiliated Hospital of Nanchang University, Nanchang, China.
  • Li J; Department of Oncology, the First Affiliated Hospital of Nanchang University, Nanchang, China.
Prostate ; 80(5): 367-375, 2020 04.
Article em En | MEDLINE | ID: mdl-31967357

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Feniltioidantoína / Neoplasias da Próstata / Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas Proto-Oncogênicas c-akt / Exenatida Tipo de estudo: Clinical_trials / Diagnostic_studies Limite: Animals / Humans / Male Idioma: En Ano de publicação: 2020 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Feniltioidantoína / Neoplasias da Próstata / Protocolos de Quimioterapia Combinada Antineoplásica / Proteínas Proto-Oncogênicas c-akt / Exenatida Tipo de estudo: Clinical_trials / Diagnostic_studies Limite: Animals / Humans / Male Idioma: En Ano de publicação: 2020 Tipo de documento: Article